Mostrar el registro sencillo del ítem
Reduction of ureteral stent encrustation by modulating the urine pH and inhibiting the crystal film with a new oral composition: a multicenter, placebo controlled, double blind, randomized clinical trial
dc.contributor.author | Torrecilla, C. | |
dc.contributor.author | Fernández-Concha, J. | |
dc.contributor.author | Cansino, J. R. | |
dc.contributor.author | Mainez, J. A. | |
dc.contributor.author | Amón, J. H. | |
dc.contributor.author | Costas, S. | |
dc.contributor.author | Angerri, O. | |
dc.contributor.author | Emiliani, E. | |
dc.contributor.author | Arrabal Martín, M. A. | |
dc.contributor.author | Arrabal Polo, M. A. | |
dc.contributor.author | García, A. | |
dc.contributor.author | Reina, M. C. | |
dc.contributor.author | Sánchez García, Juan Francisco | |
dc.contributor.author | Budía, A. | |
dc.contributor.author | Pérez Fentes, Daniel Alfonso | |
dc.contributor.author | Grases, F. | |
dc.contributor.author | Costa-Bauzá, A. | |
dc.contributor.author | Cuñé, J. | |
dc.date.accessioned | 2022-04-26T07:45:02Z | |
dc.date.available | 2022-04-26T07:45:02Z | |
dc.date.issued | 2020 | |
dc.identifier.issn | 1471-2490 | |
dc.identifier.other | https://www.ncbi.nlm.nih.gov/pubmed/32503502 | es |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/16561 | |
dc.description.abstract | BACKGROUND: Encrustation of ureteral double J stents is a common complication that may affect its removal. The aim of the proposed study is to evaluate the efficacy and safety of a new oral composition to prevent double J stent encrustation in indwelling times up to 8 weeks. METHODS: A double-blinded, multicenter, placebo-controlled trial was conducted with 105 patients with indwelling double J stents enrolled across 9 public hospitals in Spain. The patients were randomly assigned (1:1) into intervention (53 patients) or placebo (52 patients) groups for 3 to 8 weeks and both groups self-monitored daily their morning urine pH levels. The primary outcome of analysis was the degree of stent ends encrustation, defined by a 4-point score (0 - none; 3 - global encrustation) using macroscopic and electron microscopy analysis of crystals, after 3 to 8-w indwelling period. Score was exponentially transformed according to calcium levels. Secondary endpoints included urine pH decrease, stent removal, and incidence of adverse events. RESULTS: The intervention group benefits from a lower global encrustation rate of stent ends than placebo group (1% vs 8.2%; p < 0.018). Mean encrustation score was 85.12 (274.5) in the placebo group and 18.91 (102.27) in the intervention group (p < 0.025). Considering the secondary end points, treated patients reported greater urine pH decreases (p = 0.002). No differences in the incidence of adverse events were identified between the groups. CONCLUSIONS: Our data suggest that the use of this new oral composition is beneficial in the context of ureteral double J indwelling by decreasing mean, as well as global encrustation. TRIAL REGISTRATION: This trial was registered at www.clinicaltrials.gov under the name "Combined Use of a Medical Device and a Dietary Complement in Patient Urinary pH Control in Patients With an Implanted Double J Stent" with date 2nd November 2017, code NCT03343275, and URL. | en |
dc.rights | Atribución 4.0 Internacional | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.subject.mesh | Adult | * |
dc.subject.mesh | Methionine | * |
dc.subject.mesh | Middle Aged | * |
dc.subject.mesh | Ureter | * |
dc.subject.mesh | Calcinosis | * |
dc.subject.mesh | Crystallization | * |
dc.subject.mesh | Prosthesis Failure | * |
dc.subject.mesh | Urine | * |
dc.subject.mesh | Double-Blind Method | * |
dc.subject.mesh | Postoperative Complications | * |
dc.subject.mesh | Hydrogen-Ion Concentration | * |
dc.subject.mesh | Humans | * |
dc.subject.mesh | Stents | * |
dc.subject.mesh | Prospective Studies | * |
dc.subject.mesh | Phytic Acid | * |
dc.title | Reduction of ureteral stent encrustation by modulating the urine pH and inhibiting the crystal film with a new oral composition: a multicenter, placebo controlled, double blind, randomized clinical trial | en |
dc.type | Journal Article | es |
dc.authorsophos | Torrecilla, C.;Fernández-Concha, J.;Cansino, J. R.;Mainez, J. A.;Amón, J. H.;Costas, S.;Angerri, O.;Emiliani, E.;Arrabal Martín, M. A.;Arrabal Polo, M. A.;García, A.;Reina, M. C.;Sánchez, J. F.;Budía, A.;Pérez-Fentes, D.;Grases, F.;Costa-Bauzá, A.;Cuñé, J. | |
dc.identifier.doi | 10.1186/s12894-020-00633-2 | |
dc.identifier.pmid | 32503502 | |
dc.identifier.sophos | 39418 | |
dc.issue.number | 1 | es |
dc.journal.title | Bmc urology | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Uroloxía | es |
dc.organization | Servizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Uroloxía | es |
dc.page.initial | 65 | es |
dc.rights.accessRights | openAccess | |
dc.subject.decs | calcinosis | * |
dc.subject.decs | concentración de iones hidrógeno | * |
dc.subject.decs | ácido fítico | * |
dc.subject.decs | orina | * |
dc.subject.decs | fallo de prótesis | * |
dc.subject.decs | estudios prospectivos | * |
dc.subject.decs | cristalización | * |
dc.subject.decs | mediana edad | * |
dc.subject.decs | uréter | * |
dc.subject.decs | adulto | * |
dc.subject.decs | método con doble ocultación | * |
dc.subject.decs | complicaciones postoperatorias | * |
dc.subject.decs | stents | * |
dc.subject.decs | humanos | * |
dc.subject.decs | metionina | * |
dc.subject.keyword | CHUS | es |
dc.subject.keyword | CHUVI | es |
dc.typefides | Artículo Original | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 20 | es |